Novai is a disruptive British biotech start-up with an AI supported retinal biomarker for use in glaucoma and AMD clinical trials.
Novai's investors include SFC Capital, Ascension Ventures.
Novai is headquartered in Reading, United Kingdom.
Novai is a disruptive British biotech start-up with an AI supported retinal biomarker for use in glaucoma and AMD clinical trials.
Novai is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Novai — Funding & Investors." VCBacked, December 18, 2024, https://www.vcbacked.co/company/novai. Accessed August 15, 2026.
VCBacked. (2024). Novai — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/novai
{{cite web |title=Novai — Funding & Investors |url=https://www.vcbacked.co/company/novai |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated